SML1710
Talniflumate
≥98% (HPLC)
别名:
2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 5 mg/mL, clear (warmed)
储存温度
room temp
SMILES字符串
FC(F)(F)c1cc(ccc1)Nc2ncccc2C(=O)OC3OC(=O)c4c3cccc4
InChI
1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)
InChI key
ANMLJLFWUCQGKZ-UHFFFAOYSA-N
相关类别
生化/生理作用
Talniflumate is a phthalidyl ester of niflumic acid. It acts as an anti-inflammatory molecule and a mucoregulator. Talniflumate is used as a potent therapeutic for cystic fibrosis, chronic obstructive pulmonary disease and asthma. Talniflumate also inhibits the calcium-activated chloride channel hCLCA function, which is involved in mucus overproduction.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases GCNT3 expression and production of mucins in vivo and in vitro. Talniflumate improves responsiveness of pancreatic tumors to gefitinib. Talniflumate is a potent calcium-activated chloride channel (CaCC) blocker.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Nancy M Walker et al.
The Journal of pharmacology and experimental therapeutics, 317(1), 275-283 (2005-12-16)
Intestinal disease in cystic fibrosis (CF) mice closely mirrors aspects of obstructive syndromes in CF patients. The pathogenesis involves accumulation of mucoid debris in the crypts that fuse with intestinal content to form obstructing mucofeculant impactions. Treatment involves modalities that
Talniflumate (Genaera).
Knight D.
Current Opinion in Investigational Drugs, 5(5), 557-562 (2004)
Hayley Pearson et al.
Thorax, 76(1), 64-72 (2020-10-29)
Human respiratory syncytial virus (HRSV) is a common cause of respiratory tract infections (RTIs) globally and is one of the most fatal infectious diseases for infants in developing countries. Of those infected, 25%-40% aged ≤1 year develop severe lower RTIs leading to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持